Diethylstilboestrol (1 mg) in the management of castration-resistant prostate cancer.
Urol Int
; 94(3): 307-12, 2015.
Article
em En
| MEDLINE
| ID: mdl-25342383
ABSTRACT
OBJECTIVE:
To investigate the efficacy of diethylstilboestrol (DES) in patients with advanced prostate cancer refractory to androgen suppression.METHODS:
This retrospective study comprises 194 patients with prostate cancer treated with DES (1 mg daily) between 1976 and 2010. Study outcome parameters included demographic data, tumour characteristics, treatment history, prostate-specific antigen (PSA) responses, radiologic studies, adverse events and overall survival.RESULTS:
At initiation of oestrogen therapy the mean patient age was 69 years (range 48-89) and the median PSA was 96 ng/ml (range 1.9-9,500). The median duration of prior prostate cancer treatment was 29 months (range 1-365). DES was the second-line treatment in 58 patients and the third/fourth-line therapy in 136 men. A formal (≥50%) PSA response was observed in 95 patients (48.9%) and the median time to progression (TTP) was 250 days (95% CI, 180-360) for this group. An additional 62 patients (31.9%) had a partial PSA response with a median TTP of 150 days (95% CI, 92-180). Thirty-seven patients (19.1%) did not have a PSA response and the median TTP was 90 days (95% CI, 90-97). The median overall survival from the start of oestrogen therapy for the entire cohort was 576 days (95% CI, 482-690). The median overall survival of patients who had a formal (≥50%), partial (<50%) and no PSA response was 756 (95% CI, 670-1,429), 428 (95% CI, 340-630) and 329 (95% CI, 287-510) days, respectively. Thirty-nine patients (20.1%) were still alive at the end of the study. No treatment-related deaths occurred.CONCLUSIONS:
In the age of chemotherapy this study highlights the efficacy of oestrogen therapy in castration-refractory prostate cancer. The optimal point in the therapeutic pathway at which DES should be prescribed remains to be established.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Dietilestilbestrol
/
Neoplasias de Próstata Resistentes à Castração
Tipo de estudo:
Observational_studies
Limite:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Urol Int
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Reino Unido